Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas

Peinemann, Frank; Smith, L. A.; Bartel, C.

doi:10.1002/14651858.cd008216.pub4

Cited by 11 publications

(15 citation statements)

References 209 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Example 1: Non-rhabdomyosarcoma soft tissue sarcomas. 22 This systematic review evaluated autologous haematopoietic stem cell transplantation (autoHSCT) following high-dose chemotherapy (HDCT) versus standard-dose chemotherapy (SDCT) in patients with non-rhabdomyosarcoma soft tissue sarcomas (NRSTS).…”

Section: Resultsmentioning

confidence: 99%

“…In a planned update 2 years later, we were able to identify a single RCT. 22 Using different study types provided the advantage to report estimates of overall survival in the first version when RCTs were lacking. The advantage affected also the update version because the reporting of adverse events exceeded the scope of a single RCT considerably.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Development of an algorithm to provide awareness in choosing study designs for inclusion in systematic reviews of healthcare interventions: a method study

Peinemann

Kleijnen

2015

BMJ Open

Self Cite

View full text Add to dashboard Cite

Objectives:To develop an algorithm that aims to provide guidance and awareness for choosing multiple study designs in systematic reviews of healthcare interventions.Design: Method study: (1) To summarise the literature base on the topic. (2) To apply the integration of various study types in systematic reviews. (3) To devise decision points and outline a pragmatic decision tree. (4) To check the plausibility of the algorithm by backtracking its pathways in four systematic reviews.Results: (1) The results of our systematic review of the published literature have already been published. (2) We recaptured the experience from our four previously conducted systematic reviews that required the integration of various study types. (3) We chose length of follow-up (long, short), frequency of events (rare, frequent) and types of outcome as decision points (death, disease, discomfort, disability, dissatisfaction) and aligned the study design labels according to the Cochrane Handbook. We also considered practical or ethical concerns, and the problem of unavailable high-quality evidence. While applying the algorithm, disease-specific circumstances and aims of interventions should be considered. (4) We confirmed the plausibility of the pathways of the algorithm. Conclusions:We propose that the algorithm can assist to bring seminal features of a systematic review with multiple study designs to the attention of anyone who is planning to conduct a systematic review. It aims to increase awareness and we think that it may reduce the time burden on review authors and may contribute to the production of a higher quality review.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Development of an algorithm to provide awareness in choosing study designs for inclusion in systematic reviews of healthcare interventions: a method study

Peinemann

Kleijnen

2015

BMJ Open

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, a study conducted by Zhang et al analyzed a cohort of 48 patients with DSRCT and found median overall survival of 24 months; the variables associated with improved OS included “surgery, effective debulking surgery, chemotherapy, and any two or more combined therapeutics” ( p < 0.05). There was also a Cochrane Review that examined SCT in nonrhabdomyosarcoma STS, within which 27 patients carried a diagnosis of DSRCT [ 9 , 23 ]. The graph of OS of the 27 patients with DSRCT appeared similar to the graph of the 80 total patients, but there was no direct statistical comparison.…”

Section: Discussionmentioning

confidence: 99%

High-Dose Chemotherapy with Stem Cell Rescue in Desmoplastic Small Round Cell Tumor: A Single-Institution Experience and Review of the Literature

Bailey

Roth

Weiser

et al. 2018

Sarcoma

View full text Add to dashboard Cite

Purpose Desmoplastic small round cell tumor (DSRCT) is a rare cancer that predominantly affects males averaging 21 years of age at the time of diagnosis. We describe four cases from our institution and place them within the context of a comprehensive review of the literature. Patients and Methods Study population included any patient who received treatment at Children's Hospital at Montefiore (CHAM) with histologic diagnosis of DSRCT. A search of the electronic databases PubMed, Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE for the terms “desmoplastic” AND “small” AND “round” AND “cell” AND “tumor” was performed. Results One CHAM patient died of disease at 39 months, one patient has relapsed disease at 40 months, and two patients have no evidence of disease at 60 and 91 months. In the literature review, the 3-year OS was 36% and 5-year OS was 13%. There was a statistically significant difference in OS between no transplant and SCT in remission (p=0.004); however, there was no difference between no transplant and SCT not in remission (p=0.23). Conclusion Given the poor prognosis in DSRCT, this study supports further prospective research into the possible benefit of consolidation of autologous SCT in patients with DSRCT who are in remission, with the alternative inference that these patients in remission may fare well without SCT. Our retrospective review of the literature does not support SCT for patients who are not in remission.

show abstract

“… 13 Despite treatment, survival prognosis remains poor ( Table 1 ), with most patients experiencing resistant and recurrent disease before end of life. 14,15 The data on use of HIPEC in DSRCT is scarce, however, Hayes-Jordan et al showed that HIPEC has improve survival outcomes with patients receiving neoadjuvant chemotherapy followed by cytoreductive surgery and HIPEC having a 3 year survival of 71% compared to 26% ( p = 0.021) in patients who did not receive surgery or HIPEC. 1 Our follow up has been shorter and hence we were unable to make a direct comparison in terms of survival.…”

Section: Discussionmentioning

confidence: 99%

Peritonectomy and hyperthermic intraperitoneal chemotherapy as treatment for desmoplastic small round cell tumour

Fan

I’Ons

McConnell

et al. 2015

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

IntroductionThe St George Hospital specialises in peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of intra-abdominal malignancies. Despite performing around 800 peritonectomy and HIPEC procedures, we have rarely encountered desmoplastic small round cell tumours (DSRCT). We present our experiences with DSRCT, and propose peritonectomy and HIPEC as a treatment option for DSRCT.Presentation of caseThis is a case series of 3 cases. The first case was a 26-year-old male who presented with appendicitis which we diagnosed as DSRCT and treated with peritonectomy and HIPEC. The second case was a 14-year-old male referred to our centre for peritonectomy and HIPEC after initial presentation with a pelvic mass and treatment with chemotherapy. The third case was a 21-year-old male referred to our centre for peritonectomy and HIPEC for recurrent DSRCT after previously being treated with neoadjuvant chemotherapy and surgery without HIPEC.DiscussionDSRCT is a rare, almost exclusively intra-abdominal malignancy, which predominantly affects young males. Survival prognosis remains poor in DSRCT despite conventional treatment with surgery, chemotherapy and radiotherapy; however, HIPEC has offered promising survival results. Our recurrences with peritonectomy and HIPEC at 6 months and 15 months are comparable with the literature of 8.85 months.ConclusionIn our experience, patients with DSRCT who present with nodal involvement or recurrent disease tend to recur early despite treatment with peritonectomy and HIPEC. Longer term follow up of our patients and future studies involving HIPEC in DSRCT would be useful in assessing long-term clinical outcomes and survival.

show abstract

Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas

Abstract: Autologous hematopoietic stem cell transplantation following high dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas.

Cited by 11 publications

References 209 publications

Development of an algorithm to provide awareness in choosing study designs for inclusion in systematic reviews of healthcare interventions: a method study

Development of an algorithm to provide awareness in choosing study designs for inclusion in systematic reviews of healthcare interventions: a method study

High-Dose Chemotherapy with Stem Cell Rescue in Desmoplastic Small Round Cell Tumor: A Single-Institution Experience and Review of the Literature

Peritonectomy and hyperthermic intraperitoneal chemotherapy as treatment for desmoplastic small round cell tumour

Contact Info

Product

Resources

About